look rewind help move forward
tough lower target price
trulic taltz concern pressur stock updat
model compani result incorpor detail
confer call follow-up call compani controversi
pressur stock follow result larg driven
surpris quarterli miss taltz trulic well concern
around potenti futur price pressur trulic follow-up call
compani provid us reassur driver
miss one-tim natur surpris see stock
one consid two product suppos deliv
well sale growth compani expect gener
continu see lilli solid stori run
well-respect manag team think reflect current
stock price maintain neutral rate lower tp
notabl model chang lower revenu forecast
driven mainli lower sale estim trulic emgal
offset lower revenu lower spend forecast
lead ep estim increas also
remov tanezumab sale model follow recent disappoint
top-line phase data product contribut lower dcf
valuat lower target price pleas let us know would like
updat excel-bas model compani
valuat risk target price blend
discount cash flow dcf valuat rel valuat dcf
base wacc termin growth rel
valuat base new ep blue
sky valuat grey sky valuat main risk
target price neutral rate better/wors expect
commerci execut and/or surpris clinic data pipelin
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
price apr rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
trulic jardianc taltz emgal olumi verzenio
compar current base case assumpt also model higher
gross margin oper margin base case
assumpt blue sky valuat base dcf driven
wacc growth termin rate
grey sky valuat base lower sale trulic
jardianc taltz emgal olumi verzenio compar
current base case assumpt grey sky valuat base
dcf driven wacc growth termin rate
 close
sale
sale
charl martineau univers toronto follow-up lilli
opportun speak member lilli team follow confer
call gain addit clariti dynam certain product
summar compani answer question
driver trulic sale miss
fundament robust
also sens ship quarter
script growth
shipment
oversight ship wholesal
good part channel
net price effect
price compress manag care
also growth higher rebat segment dod va etc
overal lsd declin portfolio whole
show greater donut hole impact
overal impact compani
lastli adjust rebates/discount
rest year see step function chang
share gain admelog mainli manag medicaid
market
author gener exclud formulari coverag
still work payer
announc
call june pt discuss rewind
differ dynam us vs ex-u
continu growth us base
see signific eros germani gener competit
ipr vitamin regimen favor us date
altern salt form appeal hear schedul rule expect later year
class show better growth quarter
continu focu execut brand
tri get initi patient trial well maintain
patient tri product
studi later year
adjuv data
happen prexasertib chek
despit continu evid singl agent activ miss endpoint advanc
expect first lung thyroid
updat registr data meet later year
relay main data highlight
top-line came march
egfr mutant-posit lung cancer studi cyramza
submit regul global mid-year
osimertinib current soc
map kinas pathway implic solid tumor
earli phase data varieti patient includ lung
good uptak
revenu growth us script growth
script paid patient assist
main impact price
inventori burn qoq similar saw yoy
olumi us
slow steadi ra
file psoriat arthriti sinc taltz alreadi joint
look indic olumi includ atop dermat lupu
efficaci similar oral cgrp
add migrain franchis
keep close eye oral cgrp lot innov space
us focu right
phase europ japan
expect drug price reform
plan implement rebat rule januari
biggest impact patient level
right polici answer problem
access lower price
could drive better adher better volum
note new/old base pro-forma pharma-onli figur
sale
total incom expens
provis incom tax
figur revenu statement
figur revenu statement
compani mention price
